Articles From: Nuveen Closed-End Funds Declare Quarterly Distributions to Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced regular quarterly distributions for 15 Nuveen closed-end funds.

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced regular quarterly distributions for 15 Nuveen closed-end funds.

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced the Board of Trustees of certain Nuveen municipal bond closed-end funds approved a series of mergers.

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced the Nuveen Credit Strategies Income Fund (NYSE: JQC) has filed initial registration statements to establish an equity shelf program.

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced the distribution for the Nuveen Intermediate Duration Municipal Term Fund (NYSE: NID) .

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced common share distributions for three municipal closed-end funds.

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced distributions for six Nuveen New York municipal closed-end funds.

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced the distributions for four Ohio municipal closed-end funds and four Arizona municipal closed-end funds.

Nuverra Environmental Solutions, Inc. (NYSE: NES) , one of the largest companies in the United States dedicated to the removal, treatment, recycling, transportation and disposal of restricted solids, fluids and hydrocarbons, today announced that Mark D.

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0872492001&sourceType=1 http://media3.marketwire.com/docs/nva_logo.jpg CALGARY, ALBERTA --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0852471001&sourceType=1 http://media3.marketwire.com/docs/nva_logo.jpg CALGARY, ALBERTA --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0872778001&sourceType=1 http://media3.marketwire.com/docs/nva_logo.jpg CALGARY, ALBERTA --

MISSISSAUGA, ON , March 27, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2012 .

Nuvo Research announces 2012 Fourth Quarter & Year-End Results Canada NewsWire MISSISSAUGA, ON, March 27, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the fourth quarter and year ended December 31, 2012 .

MISSISSAUGA, ON , May 1, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013 .

Nuvo Research announces 2013 First Quarter Results Canada NewsWire MISSISSAUGA, ON, May 1, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013 .

Nuvo Research Inc. (TSX:NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.

Nuvo Research announces European launch of Pliaglis® by Galderma Canada NewsWire MISSISSAUGA, ON, April 23, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.

MISSISSAUGA, ON , April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.

Nuvo Research announces FDA response to PENNSAID® 2% NDA Canada NewsWire MISSISSAUGA, ON, March 5, 2013 /CNW/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV) , has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site.

MISSISSAUGA, ON , March 5, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt , the Pharmaceuticals Business of Covidien (NYSE:COV) , has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site.

Nuvo Research announces notice of Intention to Grant a European Patent for PENNSAID® 2% Canada NewsWire Forward-Looking Statements Certain statements in this news release constitute forward-looking statements within the meaning of applicable securities laws.

MISSISSAUGA, ON , May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID ® 2% product.

Nuvo Research Announces Scientific Presentation at the Annual Meeting of the American Association of Immunologists Canada NewsWire Data Evaluating WF10's Therapeutic Impact on Signs and Symptoms of Experimentally Induced Rheumatoid Arthritis in Mice MISSISSAUGA, ON, May 16, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo presented scientific data related to WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice at the 100 th Annual Meeting of The American Association of Immunologists (AAI) in Honolulu , Hawaii, U.S. Compared to the placebo group, animals treated with WF10 showed a reduction of the

Data Evaluating WF10's Therapeutic Impact on Signs and Symptoms of Experimentally Induced Rheumatoid Arthritis in Mice MISSISSAUGA, ON , May 16, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo presented scientific data related to WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice at the 100 th Annual Meeting of The American Association of Immunologists (AAI) in Honolulu, Hawaii , U.S. Compared to the placebo group, animals treated with WF10 showed a reduction of the degree of symptoms.

Nuvo Research announces scientific presentation at the Annual Meeting of the American Medical Society for Sports Medicine Canada NewsWire Data Evaluating Synera ® for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON, April 19, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera ® (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22 nd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM) in San Diego , California.

Data Evaluating Synera ® for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON , April 19, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera ® (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22 nd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM) in San Diego, California .

Data Evaluating Synera ® for the Treatment of Acute Musculoskeletal Pain to be Presented at the Scientific Meeting MISSISSAUGA, ON , May 30, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain announced that researchers presented scientific data related to the Synera (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 60 th Annual Meeting of the American College of Sports Medicine in Indianapolis, Indiana .

Nuvo Research announces scientific presentations at the Annual Meeting of the American College of Sports Medicine Canada NewsWire Data Evaluating Synera ® for the Treatment of Acute Musculoskeletal Pain to be Presented at the Scientific Meeting MISSISSAUGA, ON, May 30, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain announced that researchers presented scientific data related to the Synera (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 60 th Annual Meeting of the American College of Sports Medicine in Indianapolis , Indiana.

Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation Canada NewsWire MISSISSAUGA, ON, Jan.